Zydus Cadila Gets U.S. FDA Nod For Anesthesia Drug
Zydus Cadila today said it had received approval from the U.S. FDA to market Succinylcholine Chloride injection.
Drug firm Zydus Cadila today said it had received approval from the U.S. health regulator to market Succinylcholine Chloride injection, used as part of general anaesthesia procedure, in the American market.
The company has received approval from the United States Food and Drug Administration (U.S. FDA) to market its product in the U.S. market, Zydus Cadila said in a statement.
The medication is used as an adjunct to general anaesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
The product would be manufactured at the group's Moraiya, Ahmedabad-based formulations manufacturing facility. The company said it has also received tentative approval for Plerixafor injection, used in treating a certain type of blood cancers.
Zydus group now has more than 190 approvals from the USFDA and has so far filed over 320 abbreviated new drug applications (ANDAs) since the commencement of the filing process in the financial year 2003-04.